5 Immuno-Oncology Developments To Watch In 2018 – Forbes
Forbes |
5 Immuno-Oncology Developments To Watch In 2018
Forbes Bluebird Bio CEO Nick Leschly speaking at the recent Forbes Healthcare Summit. Bluebird is one of the companies drumming up excitement for immuno-oncology. Immuno-oncology dominated the headlines coming out of the FDA and the major cancer conferences … |
